Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2023 Earnings Call Transcript

Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2023 Earnings Call Transcript November 1, 2023 8:00 AM ET

Company Participants

Matt Calistri - Vice President of Investor Relations
Ron Renaud - President and Chief Executive Officer
Ray Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Susan Altschuller - Chief Financial Officer

Conference Call Participants

Michael Yee - Jefferies
Paul Matteis - Stifel
Mohit Bansal - Wells Fargo
Jeff Hung - Morgan Stanley
Charles Duncan - Cantor Fitzgerald
David Amsellem - Piper Sandler
Joseph Thome - TD Cowen

Operator

Good morning and welcome to the Cerevel Therapeutics Third Quarter Financial Results Conference call. At this time, all participants are in listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded.

I will now hand the call over to Matt Calistri, Vice President of Investor Relations.

Matt Calistri

Thank you. Good morning, everyone. We appreciate you joining us for our third quarter 2023 earnings call. On today's call, you'll be hearing from Ron Renaud, our President and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Dr. Susan Altschuller, our Chief Financial Officer.

During our call today, please refer to our press release from this morning, detailing our third quarter 2023 financial performance, as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties.